The Cortex Platform harnesses advances in virtual reality technology to detect brain changes early in the Alzheimer's Disease (AD) process, helping to accelerate early diagnosis for better clinical outcomes. Cortex is at the forefront of a new era to leverage Artificial Intelligence and Machine Learning to assess brain health. We offer physicians a novel way to objectively assess cognitive functions, in the most ecologically valid way, prior to the onset of AD symptoms. Based on many years of clinical data from studies, we have developed a NeuroVisuoMotor Index (NVM) that can identify Prodromal AD years before it’s actual onset.
The CORTEX platform uses individuals’ score(s) on a battery of cognitive tasks to provide an interpretation of the current level of cognitive function. It is important to recognize that cognition is not a unitary construct. Because different regions of the brain are affected differently in the four subtypes of Alzheimer’s, patients develop different ...
The Cortex Platform harnesses advances in virtual reality technology to detect brain changes early in the Alzheimer's Disease (AD) process, helping to accelerate early diagnosis for better clinical outcomes. Cortex is at the forefront of a new era to leverage Artificial Intelligence and Machine Learning to assess brain health. We offer physicians a novel way to objectively assess cognitive functions, in the most ecologically valid way, prior to the onset of AD symptoms. Based on many years of clinical data from studies, we have developed a NeuroVisuoMotor Index (NVM) that can identify Prodromal AD years before it’s actual onset.
The CORTEX platform uses individuals’ score(s) on a battery of cognitive tasks to provide an interpretation of the current level of cognitive function. It is important to recognize that cognition is not a unitary construct. Because different regions of the brain are affected differently in the four subtypes of Alzheimer’s, patients develop different symptoms and also prognoses. This knowledge is important for doctors who assess patients with Alzheimer’s, and it also makes us wonder whether the four subtypes might respond differently to different treatments. Right now, research on various drugs that reduce the amount of tau in the brain is very active, and it will be exciting to see if they vary in efficacy depending on the subtype of Alzheimer. To evaluate all measures that are used in clinical trials that are appropriate for the Prodromal stage the entire spectrum of cognitive deficits, we include a large neuropsychological battery of tests that assess information processing speed (IPS), episodic memory (EM), working memory (WM), executive functions (EF) and attention. These “gold standard” tests are currently not commercially available for use in a virtual reality platform.
Cortex holds great potential: (i) for improving both the diagnosis and prognosis of AD; (ii) for projecting the clinical and neurological evolution of AD for planning suitable directions in therapeutic mediation; (iii) in providing multiple opportunities for the more directed analysis of AD heterogeneity in a data driven manner; and (iv) in providing strategic guidelines for more decisive therapeutic intervention and the more efficacious clinical management of AD. It is designed to be used in a wide range of neurogenerative diseases.
More information

Employees

Paula Bolger, PhD
Admin
Paula Bolger, PhD CEO Dr. Bolger in a digital health expert, with 15 years experience working with Pharma Companies to deliver global digital health products.
Brendan Ryan
Admin
Brendan Ryan